Dr. Michael Chen

Biotech Science Reporter

Molecular biologist turned biotech journalist with PhD in Genetics and 9 years of experience covering drug discovery, clinical trials, and regulatory approvals. Former research scientist who transitioned to journalism to explain breakthrough therapies and biotechnology innovations. Specializes in gene therapy, immunotherapy, rare disease treatments, and the science behind novel drug mechanisms.

AI Author, more information here

How Natera’s Up‑Revised Target Reflects Its Growing CF‑DNA Diagnostic Power

Discover why Natera’s upgraded stock‑price target reflects its winning cfDNA platform, FDA‑cleared NIPT and oncology liquid biopsies, and future growth plans.

Dr. Michael Chen

16/11/2025, 10:13

5 minutes to read

Argenx Shares Surge as Robust Phase‑2 Data Boost Pipeline and Investor Confidence

Argenx shares rise on strong oncology data and a diversified bispecific pipeline, highlighting AMG 557’s melanoma success and future regulatory prospects.

Dr. Michael Chen

15/11/2025, 10:00

4 minutes to read

How Daiichi Sankyo & General Proximity Are Tackling Undruggable Oncogene Targets

Discover how Daiichi Sankyo’s partnership with General Proximity’s OmniTAC™ and its new STING‑based program could unlock undruggable oncology targets like KRAS and MYC, advancing colorectal cancer treatment.

Dr. Michael Chen

14/11/2025, 10:40

4 minutes to read

How Sartorius Stedim Biotech Fuels Growth in the Expanding Drug‑Discovery Outsourcing Market

Discover how Sartorius Stedim Biotech’s AI‑enabled lab equipment powers drug‑discovery outsourcing, driving growth with GMP‑grade solutions for pharma R&D.

Dr. Michael Chen

13/11/2025, 10:21

3 minutes to read

Illumina Surges: Analyst Upgrades, China Ban Lifted, & Strong Oncology Growth

Illumina’s analyst upgrades, China export‑ban lift and oncology NGS growth signal a bullish outlook—discover how the company’s tech, compliance and partnership strategy drive investor confidence.

Dr. Michael Chen

08/11/2025, 11:10

4 minutes to read

Haleon PLC Unveils Q3 2025 Unaudited Results, Awaiting Detailed Guidance

Haleon PLC releases unaudited Q3 2025 results, meeting SEBI LODR requirements but offering only high‑level figures, so investors await detailed earnings commentary for full insight.

Dr. Michael Chen

08/11/2025, 10:51

3 minutes to read

Merck KGaA Secures 16 MW of Renewable Power in 20‑Year PPA to Reach 80 % Clean Energy Goal

Merck KGaA secures 16 MW of renewable power in South Korea with a 20‑year PPA to hit 80 % renewable electricity by 2030, cutting CO₂ and boosting investor confidence.

Dr. Michael Chen

05/11/2025, 07:16

3 minutes to read

Incyte Q3 Revenue Surges 20% on Jakafi Demand, Boosts Growth Outlook

Incyte’s Q3 revenue jumps 20% thanks to Jakafi’s strong sales, highlighting its expanding indication portfolio and promising pipeline for future growth.

Dr. Michael Chen

31/10/2025, 11:02

3 minutes to read

Thermo Fisher Acquires Clario for $8.875B, Expanding Cloud‑Based Clinical Data Services

Thermo Fisher’s $8.875 billion acquisition of Clario Holdings expands its clinical research services with cloud‑based data analytics, real‑time monitoring, and regulatory‑aligned data solutions, boosting CRS revenue and accelerating biopharma trials.

Dr. Michael Chen

30/10/2025, 13:07

4 minutes to read

Argenx SE Reports Strong Q3 Results with VYVGART Driving Revenue Surge and Market Confidence

Argenx SE, a European biotechnology firm, has reported a 95.3% year-over-year increase in revenue, driven by strong sales of its flagship antibody therapy, VYVGART, which has shown promising efficacy in treating seropositive generalized myasthenia g…

Dr. Michael Chen

30/10/2025, 08:16

3 minutes to read

Older articles